4-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-pyrrole-2-carbonitrile | 1032649-11-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-pyrrole-2-carbonitrile
• 英文别名: 4-[2,2,2-trifluoro-1-[1-(4-fluorophenyl)indazol-5-yl]-1-hydroxyethyl]-1H-pyrrole-2-carbonitrile
• CAS: 1032649-11-8
• 化学式: C₂₀H₁₂F₄N₄O
• 分子量: 400.335
• InChiKey: RGXDZPPJDREFGB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  77.6
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES
  申请人：GRIFFIOEN Gerard

  公开号：US20100197703A1

  公开（公告）日：2010-08-05

  This invention provides thiazolylpiperazine derivatives, and N-sulfonyl heterocyclic derivatives including phenyl- and benzyl-thiazolylpiperidine derivatives, and pharmaceutically acceptable salts thereof, which are useful active ingredients for administration in a method for the treatment of an α-synucleopathy such as Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and Alzheimer's disease. This invention also provides methods for making such derivatives, and pharmaceutical compositions including such derivatives together with pharmaceutically acceptable excipients.

  该发明提供了噻唑基哌嗪衍生物，以及包括苯基和苄基噻唑基哌啶衍生物的N-磺酰杂环衍生物，以及其药学上可接受的盐，这些是用于治疗α-突触核蛋白病的有效活性成分，如帕金森病、弥漫性小体病、创伤性脑损伤、肌萎缩侧索硬化症、尼曼-匹克病、哈勒沃登-施帕茨综合征、唐氏综合征、神经轴突萎缩、多系统萎缩和阿尔茨海默病的治疗方法。该发明还提供了制备这些衍生物的方法，以及包括这些衍生物和药学上可接受的辅料的药物组合物。
• Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof
  申请人：Kuzmich Daniel

  公开号：US20100197678A1

  公开（公告）日：2010-08-05

  Compounds of Formula (IA) wherein R 1 , R 2 , R 3 , A, B, C, D, E, G, X, Y, and Z are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

  该文提到的化合物的分子式为（IA），其中R1，R2，R3，A，B，C，D，E，G，X，Y和Z的定义如本文所述，或其自身的异构体，前药，溶剂化物或盐；包含这些化合物的药物组合物，以及使用这些化合物调节糖皮质激素受体功能的方法，以及治疗由糖皮质激素受体功能介导或以炎症，过敏或增生过程为特征的疾病状态或情况的方法。
• Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto
  申请人：Arena Pharmaceuticals, Inc.

  公开号：US10479797B2

  公开（公告）日：2019-11-19

  The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a beta-3 adrenergic receptor-mediated disorder, such as, heart failure; cardiac performance in heart failure; mortality, reinfarction, and/or hospitalization in connection with heart failure; acute heart failure; acute decompensated heart failure; congestive heart failure; severe congestive heart failure; organ damage associated with heart failure (e.g., kidney damage or failure, heart valve problems, heart rhythm problems, and/or liver damage); heart failure due to left ventricular dysfunction; heart failure with normal ejection fraction; cardiovascular mortality following myocardial infarction; cardiovascular mortality in patients with left ventricular failure or left ventricular dysfunction; left ventricular failure; left ventricular dysfunction; class II heart failure using the New York Heart Association (NYHA) classification system; class III heart failure using the New York Heart Association (NYHA) classification system; class IV heart failure using the New York Heart Association (NYHA) classification system; LVEF<40% by radionuclide ventriculography; LVEF≤35% by echocardiography or ventricular contrast angiography; and conditions related thereto.

  本发明涉及调节β-3肾上腺素能受体活性的式(Ia)化合物及其药物组合物。本发明的化合物及其药物组合物用于治疗β-3肾上腺素能受体介导的疾病，如心力衰竭；心力衰竭时的心脏表现；与心力衰竭有关的死亡率、再梗塞和/或住院治疗；急性心力衰竭；急性失代偿性心力衰竭；充血性心力衰竭；严重充血性心力衰竭；与心力衰竭有关的器官损伤（如：肾脏损伤或衰竭、心脏瓣膜问题、心律问题等）、左心室功能不全导致的心力衰竭；射血分数正常的心力衰竭；心肌梗塞后的心血管死亡率；左心室功能不全或左心室功能障碍患者的心血管死亡率；左心室功能不全；左心室功能障碍；根据纽约心脏协会（NYHA）分类系统划分的Ⅱ级心力衰竭；根据纽约心脏协会（NYHA）分类系统划分的Ⅲ级心力衰竭；根据纽约心脏协会（NYHA）分类系统划分的Ⅳ级心力衰竭；根据放射性核素心室造影检查，LVEF<40%；根据超声心动图或心室造影血管造影检查，LVEF≤35%；以及与此相关的情况。
• Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides
  申请人：UCB PHARMA GMBH

  公开号：US11345662B2

  公开（公告）日：2022-05-31

  Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.

  所公开的磺酰胺化合物具有调节 GPR17 的特性，可用于治疗或预防各种中枢神经系统疾病和其他疾病，特别是预防和治疗髓鞘疾病或紊乱。
• GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2102170A2

  公开（公告）日：2009-09-23